Roche expands access to clinical trial data

Roche has said it will increase access to its clinical trial data for third-party researchers in a bid to
boost transparency.

The move comes after a difficult period for the company in which it has been roundly criticized
in the British Medical Journal for withholding data on its flu drug Tamiflu (oseltamivir), raising
speculation that is was not as effective as claimed by the company.

Responding to the criticism, Roche now says it will work with an independent body of recognized
experts to evaluate and approve requests to access anonymised patient-level data.